TY - JOUR
T1 - Psoriasis
T2 - Emerging therapeutic strategies
AU - Gottlieb, Alice B.
N1 - Funding Information:
This work was funded in part by grants from the David Ju Foundation and a Center of Excellence grant from the Federation of Clinical Immunology Societies (FOCIS).
PY - 2005/1
Y1 - 2005/1
N2 - Psoriasis is a chronic inflammatory skin disorder that is characterized by thickened, scaly plaques, and is estimated to affect ∼ 1-3% of the Caucasian population. Traditional treatments, although effective in patients with limited disease, have numerous shortcomings, including inconvenience and toxicity. These drawbacks mean that many patients experience cycles of disease clearance, in which normal quality of life alternates with active disease and poor quality of life. However, as this review discusses, recent advances have highlighted the key role of the immune system in the pathogenesis of psoriasis, and have provided new defined targets for therapeutic intervention, offering hope for safe and effective psoriasis treatment.
AB - Psoriasis is a chronic inflammatory skin disorder that is characterized by thickened, scaly plaques, and is estimated to affect ∼ 1-3% of the Caucasian population. Traditional treatments, although effective in patients with limited disease, have numerous shortcomings, including inconvenience and toxicity. These drawbacks mean that many patients experience cycles of disease clearance, in which normal quality of life alternates with active disease and poor quality of life. However, as this review discusses, recent advances have highlighted the key role of the immune system in the pathogenesis of psoriasis, and have provided new defined targets for therapeutic intervention, offering hope for safe and effective psoriasis treatment.
UR - http://www.scopus.com/inward/record.url?scp=12144281223&partnerID=8YFLogxK
U2 - 10.1038/nrd1607
DO - 10.1038/nrd1607
M3 - Review article
C2 - 15688070
AN - SCOPUS:12144281223
SN - 1474-1776
VL - 4
SP - 19
EP - 34
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 1
ER -